Nuclear receptors, inflammation, and neurodegenerative diseases

Advances in Immunology

Volumn 106, Issue C, 2010, Pages 21-59

  Saijo, Kaoru ^a   Crotti, Andrea ^a   Glass, Christopher K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ALITRETINOIN; CALCITRIOL; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLITAZONE DERIVATIVE; GLUCOCORTICOID RECEPTOR; LIVER X RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR RELATED FACTOR 1; ORPHAN NUCLEAR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR ALPHA; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CELL RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; ATHEROSCLEROSIS; B LYMPHOCYTE; BOOK; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN RESISTANCE; MICROGLIA; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; T LYMPHOCYTE; ANIMAL; CHEMISTRY; COMPLICATION; CYTOLOGY; FEMALE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE; MALE; METABOLISM; NEURODEGENERATIVE DISEASES;

ADAPTIVE IMMUNITY; ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; INFLAMMATION; LYMPHOCYTES; MALE; MICROGLIA; NEURODEGENERATIVE DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 77955911207     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/S0065-2776(10)06002-5     Document Type: Chapter

References (201)

1. Aarnisalo P., Kim C.H., Lee J.W., Perlmann T. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1. J. Biol. Chem. 2002, 277:35118-35123.
2. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
3. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008, 4:404-412.
4. A-Gonzalez N., Bensinger S.J., Hong C., Beceiro S., Bradley M.N., Zelcer N., Deniz J., Ramirez C., Diaz M., Gallardo G., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
5. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003, 289:2819-2826.
6. Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007, 10:1538-1543.
7. Akiyama H. Inflammatory response in Alzheimer's disease. Tohoku J. Exp. Med. 1994, 174:295-303.
8. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
9. Appel S.H., Beers D.R., Henkel J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: Are we listening?. Trends Immunol. 2010, 31:7-17.
10. Arbel M., Solomon B. Immunotherapy for Alzheimer's disease: Attacking amyloid-beta from the inside. Trends Immunol. 2007, 28:511-513.
11. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of I κ B synthesis. Science 1995, 270:286-290.
12. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
13. Banerjee R., Mosley R.L., Reynolds A.D., Dhar A., Jackson-Lewis V., Gordon P.H., Przedborski S., Gendelman H.E. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 2008, 3:e2740.
14. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 2010, 37:26-32.
15. Barish G.D., Downes M., Alaynick W.A., Yu R.T., Ocampo C.B., Bookout A.L., Mangelsdorf D.J., Evans R.M. A nuclear receptor atlas: Macrophage activation. Mol. Endocrinol. 2005, 19:2466-2477.
16. Bauer J., Rauschka H., Lassmann H. Inflammation in the nervous system: The human perspective. Glia 2001, 36:235-243.
17. Beck I.M., Vanden Berghe W., Vermeulen L., Bougarne N., Vander Cruyssen B., Haegeman G., De Bosscher K. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-κB inhibition. EMBO J. 2008, 27:1682-1693.
18. Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA 2008, 105:15558-15563.
19. Benner E.J., Banerjee R., Reynolds A.D., Sherman S., Pisarev V.M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R.L., et al. Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008, 3:e1376.
20. Bertram L., Tanzi R.E. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat. Rev. Neurosci. 2008, 9:768-778.
21. Bielekova B., Becker B.L. Monoclonal antibodies in MS: Mechanisms of action. Neurology 2010, 74(Suppl. 1):S31-S40.
22. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
23. Bonta P.I., van Tiel C.M., Vos M., Pols T.W., van Thienen J.V., Ferreira V., Arkenbout E.K., Seppen J., Spek C.A., van der Poll T., et al. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2288-2294.
24. Bourguet W., Ruff M., Bonnier D., Granger F., Boeglin M., Chambon P., Moras D., Gronemeyer H. Purification, functional characterization, and crystallization of the ligand binding domain of the retinoid X receptor. Protein Expr. Purif. 1995, 6:604-608.
25. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
26. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
27. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
28. Brodbeck J., Balestra M.E., Saunders A.M., Roses A.D., Mahley R.W., Huang Y. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc. Natl Acad. Sci. USA 2008, 105:1343-1346.
29. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
30. Caelles C., Gonzalez-Sancho J.M., Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 1997, 11:3351-3364.
31. Carrithers M.D., Visintin I., Kang S.J., Janeway C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123(Pt. 6):1092-1101.
32. Castano A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 1998, 70:1584-1592.
33. Castrillo A., Joseph S.B., Marathe C., Mangelsdorf D.J., Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 2003, 278:10443-10449.
34. Castrillo A., Joseph S.B., Vaidya S.A., Haberland M., Fogelman A.M., Cheng G., Tontonoz P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12:805-816.
35. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab. Res. Rev. 2008, 24:14-26.
36. Chan W.Y., Kohsaka S., Rezaie P. The origin and cell lineage of microglia: New concepts. Brain Res. Rev. 2007, 53:344-354.
37. Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. USA 2008, 105:17913-17918.
38. Cho I.J., Kim S.G. A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR. Mol. Endocrinol. 2009, 23:86-99.
39. Cho N., Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: From the discovery to recent progress. Curr. Top. Med. Chem. 2008, 8:1483-1507.
40. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
41. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
42. Dahten A., Mergemeier S., Worm M. PPARγ expression profile and its cytokine driven regulation in atopic dermatitis. Allergy 2007, 62:926-933.
43. Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., Gan W.B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
44. De Bosscher K., Vanden Berghe W., Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: Molecular mechanisms for gene repression. Endocr. Rev. 2003, 24:488-522.
45. Defaux A., Zurich M.G., Braissant O., Honegger P., Monnet-Tschudi F. Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. J. Neuroinflammation 2009, 6:15.
46. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NF κB and iNOS activation. J. Neurochem. 2004, 88:494-501.
47. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2002, 168:2508-2515.
48. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:116-126.
49. Dunn S.E., Ousman S.S., Sobel R.A., Zuniga L., Baranzini S.E., Youssef S., Crowell A., Loh J., Oksenberg J., Steinman L. Peroxisome proliferator-activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J. Exp. Med. 2007, 204:321-330.
50. Engelhardt B., Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol. 2005, 26:485-495.
51. Fabriek B.O., Van Haastert E.S., Galea I., Polfliet M.M., Dopp E.D., Van Den Heuvel M.M., Van Den Berg T.K., De Groot C.J., Van Der Valk P., Dijkstra C.D. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005, 51:297-305.
52. Fernandes de Abreu D.A., Eyles D., Feron F. Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009, 34(Suppl. 1):S265-S277.
53. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
54. Fouser L.A., Wright J.F., Dunussi-Joannopoulos K., Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol. Rev. 2008, 226:87-102.
55. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-The plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
56. Fukazawa T., Yabe I., Kikuchi S., Sasaki H., Hamada T., Miyasaka K., Tashiro K. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J. Neurol. Sci. 1999, 166:47-52.
57. Galea I., Palin K., Newman T.A., Van Rooijen N., Perry V.H., Boche D. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia 2005, 49:375-384.
58. Gasser T. Molecular pathogenesis of Parkinson disease: Insights from genetic studies. Expert Rev. Mol. Med. 2009, 11:e22.
59. German D.C., Eisch A.J. Mouse models of Alzheimer's disease: Insight into treatment. Rev. Neurosci. 2004, 15:353-369.
60. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 2007, 25:57-70.
61. Ghisletti S., Huang W., Jepsen K., Benner C., Hardiman G., Rosenfeld M.G., Glass C.K. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
62. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
63. Gold S.M., Voskuhl R.R. Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res. 2009, 175:239-251.
64. Gorman S., Kuritzky L.A., Judge M.A., Dixon K.M., McGlade J.P., Mason R.S., Finlay-Jones J.J., Hart P.H. Topically applied 1, 25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol. 2007, 179:6273-6283.
65. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
66. Graber D.J., Levy M., Kerr D., Wade W.F. Neuromyelitis optica pathogenesis and aquaporin 4. J. Neuroinflammation 2008, 5:22.
67. Granic I., Dolga A.M., Nijholt I.M., van Dijk G., Eisel U.L. Inflammation and NF-κB in Alzheimer's disease and diabetes. J. Alzheimers Dis. 2009, 16:809-821.
68. Gregori S., Giarratana N., Smiroldo S., Uskokovic M., Adorini L. A 1alpha, 25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
69. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005, 11:328-334.
70. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
71. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 2008, 9:857-865.
72. Harrington W.R., Kim S.H., Funk C.C., Madak-Erdogan Z., Schiff R., Katzenellenbogen J.A., Katzenellenbogen B.S. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 2006, 20:491-502.
73. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387:733-736.
74. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
75. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
76. Hindinger C., Hinton D.R., Kirwin S.J., Atkinson R.D., Burnett M.E., Bergmann C.C., Stohlman S.A. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2006, 84:1225-1234.
77. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
78. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
79. Huang W., Ghisletti S., Perissi V., Rosenfeld M.G., Glass C.K. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR depresssion checkpoint. Mol. Cell 2009, 35:48-57.
80. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
81. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., Wei D., Goldfarb K.C., Santee C.A., Lynch S.V., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
82. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
83. Jetten A.M. Retinoid-related orphan receptors (RORs): Critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal. 2009, 7:e003.
84. Jiang C., Ting A.T., Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
85. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008, 58:681-693.
86. Jin J.J., Kim H.D., Maxwell J.A., Li L., Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 2008, 5:23.
87. Jones A., Kulozik P., Ostertag A., Herzig S. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J. Alzheimers Dis. 2009, 16:787-808.
88. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
89. Joseph S.B., Bradley M.N., Castrillo A., Bruhn K.W., Mak P.A., Pei L., Hogenesch J., O'Connell R.M., Cheng G., Saez E., et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004, 119:299-309.
90. Kadkhodaei B., Ito T., Joodmardi E., Mattsson B., Rouillard C., Carta M., Muramatsu S., Sumi-Ichinose C., Nomura T., Metzger D., et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 2009, 29:15923-15932.
91. Kamer A.R., Dasanayake A.P., Craig R.G., Glodzik-Sobanska L., Bry M., de Leon M.J. Alzheimer's disease and peripheral infections: The possible contribution from periodontal infections, model and hypothesis. J. Alzheimers Dis. 2008, 13:437-449.
92. Kang Z., Altuntas C.Z., Gulen M.F., Liu C., Giltiay N., Qin H., Liu L., Qian W., Ransohoff R.M., Bergmann C., et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010, 32:414-425.
93. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996, 4:313-319.
94. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003, 4:337-342.
95. Kitazawa M., Yamasaki T.R., LaFerla F.M. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. N. Y. Acad. Sci. 2004, 1035:85-103.
96. Klaholz B.P., Renaud J.P., Mitschler A., Zusi C., Chambon P., Gronemeyer H., Moras D. Conformational adaptation of agonists to the human nuclear receptor RARγ. Nat. Struct. Biol. 1998, 5:199-202.
97. Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., Heneka M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 2005, 175:4948-4955.
98. Klotz L., Burgdorf S., Dani I., Saijo K., Flossdorf J., Hucke S., Alferink J., Novak N., Beyer M., Mayer G., et al. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 2009, 206:2079-2089.
99. Kojro E., Postina R. Regulated proteolysis of RAGE and AβPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:865-878.
100. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
101. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., Kalled S.L., Hess D.M., Serafini B., Aloisi F., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 2005, 201:195-200.
102. Kuiper G.G., Gustafsson J.A. The novel estrogen receptor-beta subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997, 410:87-90.
103. Lamkanfi M., Dixit V.M. Inflammasomes: Guardians of cytosolic sanctity. Immunol. Rev. 2009, 227:95-105.
104. Lassmann H., Bruck W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 2001, 7:115-121.
105. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
106. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 2003, 33:85-89.
107. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., Curtiss L.K. Transcriptional repression of atherogenic inflammation: Modulation by PPARδ. Science 2003, 302:453-457.
108. Lee J.H., Park S.M., Kim O.S., Lee C.S., Woo J.H., Park S.J., Joe E.H., Jou I. Differential SUMOylation of LXRα and LXRβ mediates transrepression of STAT1 inflammatory signaling in IFN-γ-stimulated brain astrocytes. Mol. Cell 2009, 35:806-817.
109. Lefterov I., Bookout A., Wang Z., Staufenbiel M., Mangelsdorf D., Koldamova R. Expression profiling in APP23 mouse brain: Inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener. 2007, 2:20.
110. Lemke G., Rothlin C.V. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 2008, 8:327-336.
111. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
112. Lichtlen P., Mohajeri M.H. Antibody-based approaches in Alzheimer's research: Safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 2008, 104:859-874.
113. Loane D.J., Deighan B.F., Clarke R.M., Griffin R.J., Lynch A.M., Lynch M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30:920-931.
114. Luchsinger J.A., Gustafson D.R. Adiposity, type 2 diabetes, and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:693-704.
115. Lue L.F., Walker D.G., Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 2001, 22:945-956.
116. Luecke H.F., Yamamoto K.R. The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev. 2005, 19:1116-1127.
117. Maira M., Martens C., Philips A., Drouin J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol. Cell. Biol. 1999, 19:7549-7557.
118. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83:835-839.
119. Martinon F., Mayor A., Tschopp J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
120. McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol. Aging 2007, 28:639-647.
121. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474.
122. Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell 2010, 140:771-776.
123. Meredith G.E., Totterdell S., Potashkin J.A., Surmeier D.J. Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S112-S115.
124. Meuth S.G., Kleinschnitz C., Wiendl H. Recent clinical trials and future therapies. J. Neurol. 2008, 255(Suppl. 6):93-96.
125. Migliore L., Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 2009, 667:82-97.
126. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
127. Mukundan L., Odegaard J.I., Morel C.R., Heredia J.E., Mwangi J.W., Ricardo-Gonzalez R.R., Goh Y.P., Eagle A.R., Dunn S.E., Awakuni J.U., et al. PPAR-δ senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 2009, 15:1266-1272.
128. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997, 89:373-380.
129. Neymotin A., Petri S., Calingasan N.Y., Wille E., Schafer P., Stewart C., Hensley K., Beal M.F., Kiaei M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 220:191-197.
130. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
131. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395:137-143.
132. O'Quinn D.B., Palmer M.T., Lee Y.K., Weaver C.T. Emergence of the Th17 pathway and its role in host defense. Adv. Immunol. 2008, 99:115-163.
133. Odegaard J.I., Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:619-626.
134. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
135. Offner H. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis. J. Neurosci. Res. 2004, 78:603-624.
136. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
137. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
138. Pappu R., Ramirez-Carrozzi V., Ota N., Ouyang W., Hu Y. The IL-17 family cytokines in immunity and disease. J. Clin. Immunol. 2010, 30:185-195.
139. Park J.Y., Kim K.S., Lee S.B., Ryu J.S., Chung K.C., Choo Y.K., Jou I., Kim J., Park S.M. On the mechanism of internalization of α-synuclein into microglia: Roles of ganglioside GM1 and lipid raft. J. Neurochem. 2009, 110:400-411.
140. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005, 437:759-763.
141. Pei L., Castrillo A., Chen M., Hoffmann A., Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J. Biol. Chem. 2005, 280:29256-29262.
142. Perissi V., Dasen J.S., Kurokawa R., Wang Z., Korzus E., Rose D.W., Glass C.K., Rosenfeld M.G. Factor-specific modulation of CREB-binding protein acetyltransferase activity. Proc. Natl. Acad. Sci. USA 1999, 96:3652-3657.
143. Perry V.H., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 2007, 7:161-167.
144. Quante T., Ng Y.C., Ramsay E.E., Henness S., Allen J.C., Parmentier J., Ge Q., Ammit A.J. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am. J. Respir. Cell Mol. Biol. 2008, 39:208-217.
145. Ramasamy R., Yan S.F., Schmidt A.M. RAGE: Therapeutic target and biomarker of the inflammatory response-The evidence mounts. J. Leukoc. Biol. 2009, 86:505-512.
146. Ransohoff R.M., Perry V.H. Microglial physiology: Unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
147. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378:681-689.
148. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
149. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., Gage F.H., Glass C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
150. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2009, (in press).
151. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
152. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-γ-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
153. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 2001, 108:1263-1282.
154. Shao G., Heyman R.A., Schulman I.G. Three amino acids specify coactivator choice by retinoid X receptors. Mol. Endocrinol. 2000, 14:1198-1209.
155. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95:927-937.
156. Shimoda K., van Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., Chu C., Quelle F.W., Nosaka T., Vignali D.A., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996, 380:630-633.
157. Shirai Y. On the transplantation of the rat sarcoma in adult heterogeneous animals. Japan Med. World 1921, 1:14-15.
158. Smolders J., Peelen E., Thewissen M., Menheere P., Cohen Tervaert J.W., Hupperts R., Damoiseaux J. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun. Rev. 2009, 8:621-626.
159. Sofroniew M.V., Vinters H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010, 119:7-35.
160. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
161. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 2009, (in press).
162. Storer P.D., Xu J., Chavis J., Drew P.D. Peroxisome proliferator-activated receptor-γ agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis. J. Neuroimmunol. 2005, 161:113-122.
163. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
164. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
165. Sturchler-Pierrat C., Sommer B. Transgenic animals in Alzheimer's disease research. Rev. Neurosci. 1999, 10:15-24.
166. Sun Z., Unutmaz D., Zou Y.R., Sunshine M.J., Pierani A., Brenner-Morton S., Mebius R.E., Littman D.R. Requirement for RORγ in thymocyte survival and lymphoid organ development. Science 2000, 288:2369-2373.
167. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
168. Szodoray P., Nakken B., Gaal J., Jonsson R., Szegedi A., Zold E., Szegedi G., Brun J.G., Gesztelyi R., Zeher M., et al. The complex role of vitamin D in autoimmune diseases. Scand. J. Immunol. 2008, 68:261-269.
169. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
170. Tajouri L., Ovcaric M., Curtain R., Johnson M.P., Griffiths L.R., Csurhes P., Pender M.P., Lea R.A. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J. Neurogenet. 2005, 19:25-38.
171. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., Nakanishi K., Yoshida N., Kishimoto T., Akira S. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
172. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
173. Tan E.K., Chung H., Chandran V.R., Tan C., Shen H., Yew K., Pavanni R., Puvan K.A., Wong M.C., Teoh M.L., et al. Nurr1 mutational screen in Parkinson's disease. Mov. Disord. 2004, 19:1503-1505.
174. Thery C., Stanley E.R., Mallat M. Interleukin 1 and tumor necrosis factor-alpha stimulate the production of colony-stimulating factor 1 by murine astrocytes. J. Neurochem. 1992, 59:1183-1186.
175. Tiwari-Woodruff S., Morales L.B., Lee R., Voskuhl R.R. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)α and ERβ ligand treatment. Proc. Natl Acad. Sci. USA 2007, 104:14813-14818.
176. Tontonoz P., Spiegelman B.M. Fat and beyond: The diverse biology of PPARγ. Annu. Rev. Biochem. 2008, 77:289-312.
177. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., Rosenfeld M.G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387:677-684.
178. Trapp B.D., Nave K.A. Multiple sclerosis: An immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
179. Valledor A.F., Hsu L.C., Ogawa S., Sawka-Verhelle D., Karin M., Glass C.K. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl Acad. Sci. USA 2004, 101:17813-17818.
180. van de Veerdonk F.L., Gresnigt M.S., Kullberg B.J., van der Meer J.W., Joosten L.A., Netea M.G. Th17 responses and host defense against microorganisms: An overview. BMB Rep. 2009, 42:776-787.
181. Vegeto E., Pollio G., Ciana P., Maggi A. Estrogen blocks inducible nitric oxide synthase accumulation in LPS-activated microglia cells. Exp. Gerontol. 2000, 35:1309-1316.
182. Villacorta L., Schopfer F.J., Zhang J., Freeman B.A., Chen Y.E. PPARγ and its ligands: Therapeutic implications in cardiovascular disease. Clin. Sci. (Lond.) 2009, 116:205-218.
183. Wang Z., Benoit G., Liu J., Prasad S., Aarnisalo P., Liu X., Xu H., Walker N.P., Perlmann T. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 2003, 423:555-560.
184. Webb P., Anderson C.M., Valentine C., Nguyen P., Marimuthu A., West B.L., Baxter J.D., Kushner P.J. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol. Endocrinol. 2000, 14:1976-1985.
185. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
186. Wust S., van den Brandt J., Tischner D., Kleiman A., Tuckermann J.P., Gold R., Luhder F., Reichardt H.M. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:8434-8443.
187. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., Husemann J. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 2003, 9:453-457.
188. Xiao Y., Xu J., Wang S., Mao C., Jin M., Ning G., Zhang Y. Genetic ablation of steroid receptor coactivator-3 promotes PPAR-β-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis. Glia 2010, 58:932-942.
189. Xu J., Storer P.D., Chavis J.A., Racke M.K., Drew P.D. Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 2005, 81:403-411.
190. Xu J., Barger S.W., Drew P.D. The PPAR-gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: Potential relevance to Alzheimer's disease. PPAR Res. 2008, 2008:349185.
191. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
192. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
193. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., Ma L., Shah B., Panopoulos A.D., Schluns K.S., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008, 28:29-39.
194. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
195. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl Acad. Sci. USA 2007, 104:10601-10606.
196. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997, 276:248-250.
197. Zhang-Gandhi C.X., Drew P.D. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 2007, 183:50-59.
198. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.
199. Zheng K., Heydari B., Simon D.K. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 2003, 60:722-725.
200. Zhou G., Cummings R., Li Y., Mitra S., Wilkinson H.A., Elbrecht A., Hermes J.D., Schaeffer J.M., Smith R.G., Moller D.E. Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer. Mol. Endocrinol. 1998, 12:1594-1604.
201. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., Cohen H., Kipnis J., Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 9:268-275.